Alertix homepage – now in English

Welcome to Alertix Veterinary Diagnostic’s international website .

We hope you will find it useful and that you will find relevant information about the company and our immunodiagnostic assays – but also about the research behind our products and about cancer diseases in companion animals.

The site is responsive. It works as well on your computer as on your tablet or smartphone.

If you have questions or thoughts regarding functionality or content, be sure to let us know. Send an e-mail to: info@alertixvet.com.

The homepage is developed and designed by AO Media. Web content is produced by Attentum Kommunikation.

Alertix Canine

Assay for early detection, monitoring and screening of tumor diseases in dogs. The assay is available to veterinary clinics and laboratories in Sweden and Scandinavia.

Alertix Feline

Assay for early detection, monitoring and screening of tumor diseases in cats. The assay is under development.

Alertix Equine

Assay for early detection, monitoring and screening of tumor diseases in horses. The assay is under development.

Under development

About cancer in companion animals

Did you know that our companion animals are afflicted by cancer as often as humans? Dogs and cats share not only our living environment but also our lifestyle. Because of this they are exposed to the same risk factors for cancer. Veterinary care is getting better and better at treating cancer in companion animals. But the crucial factor of success is that the disease is detected in time.

News

TK1 in cats

A recently published scientific paper by researchers associated with Alertix displays TK1 in cat serum to be significantly higher compared to healthy cats and compared to cats with inflammatory diseases. These results suggest that serum TK1 may be a promising biomarker for the diagnosis and monitoring of malignant diseases and for the differential diagnosis of certain inflammatory diseases.

New Board Member

M.Sc. Göran Beijer was elected as a new board member of Alertix at an extraordinary general meeting on the 17th of December 2019.

Support from Vinnova

More support for Alertix’ acclaimed research. This time from Sweden’s Innovation Agency Vinnova.

More news